Skip to main content
. Author manuscript; available in PMC: 2019 Jun 1.
Published in final edited form as: Breast Cancer Res Treat. 2018 Feb 1;169(2):381–390. doi: 10.1007/s10549-018-4685-2

Figure 1. TU-BcX-2O0, had a distinct gross appearance and tumor growth pattern and has a consistent cytology throughout passages.

Figure 1

(a) Patient data from TU-BcX-200 shows it is categorized as TNBC based on the PAM50 molecular subtype without lymph node (N0) or distant metastases (M0) involvement at the time of tumor resection. (b) Gross appearance of TU-BcX-2O0 was consistent throughout consecutive passages. The tumor had distinct pockets filled with a pustulate-like substance that was liquid when dissected. (c) Tumor growth patterns of TU-BcX-2O0 after initial engraftment into the mfp of SCID/Beige mice. Tumor growth indicates the number of days from when the tumor first became palpable to when tumors were extracted (at a final volume of 750–1000 mm3). (d) The primary specimen (obtained post-op, not yet engrafted into SCID/Beige mice) histology was compared to lower (T2) and higher passage (T5) PDX tumors. H & E stained images were captured at 10×, 20× and 40×. (e) Proliferation rate determined by Ki-67 immunohistochemistry staining of TU-BcX-2O0T5 PDX tumor compared to negative control.